Spire Wealth Management’s Anixa Biosciences ANIX Stock Holding History

Spire Wealth Management’s Portfolio ANIX Stock Details ANIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-2,500	Closed	-$11K	–	2478
2022 Q4	$11K	Sell	2,500 -12,000	-83%	-$57.7K	﹤0.01%	1563
2022 Q3	$71K	Hold	14,500	–	–	﹤0.01%	822
2022 Q2	$44K	Hold	14,500	–	–	﹤0.01%	1338
2022 Q1	$40K	Hold	14,500	–	–	﹤0.01%	1525
2021 Q4	$43K	Hold	14,500	–	–	﹤0.01%	1795
2021 Q3	$69K	Sell	14,500 -3,000	-17%	-$13.5K	﹤0.01%	1341
2021 Q2	$68K	Sell	17,500 -6,800	-28%	-$29K	﹤0.01%	1350
2021 Q1	$114K	Buy	+24,300	New	+$116K	﹤0.01%	1346

Other funds holding ANIX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Spire Wealth Management's ANIX Position: Q1 2023 in Review

Spire Wealth Management sold out of Anixa Biosciences (ANIX) in Q1 2023, closing a stake of 2,500 shares — an estimated $11K sold.

Spire Wealth Management first reported a position in ANIX in Q1 2021 and held it in 8 quarters. The position peaked at $114K in Q1 2021. 44 funds tracked by Wall St. Rank hold ANIX as of Q1 2023.

Spire Wealth Management reported no remaining Anixa Biosciences position as of Q1 2023 after selling out during the quarter.
Spire Wealth Management sold 2,500 Anixa Biosciences shares in Q1 2023, an estimated $11K.
Spire Wealth Management first reported a position in Anixa Biosciences in Q1 2021 and held it in 8 quarters.
Spire Wealth Management's Anixa Biosciences position peaked at $114K in Q1 2021.
44 funds tracked by Wall St. Rank held Anixa Biosciences as of Q1 2023.

Based on Spire Wealth Management's 13F filing for Q1 2023, filed 9 May 2023.